EE168 Avoidable Costs in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated with Darolutamide
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.467
https://www.valueinhealthjournal.com/article/S1098-3015(24)00582-5/fulltext
Title :
EE168 Avoidable Costs in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated with Darolutamide
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00582-5&doi=10.1016/j.jval.2024.03.467
First page :
Section Title :
Open access? :
No
Section Order :
11807